Resmetirom 治疗 MASH:MAESTRO-NASH III 期试验中 qFibrosis 定量回归分析
MAESTRO-NASH III 期试验对 966 例经活检确诊的 MASH 且纤维化分期为 F1B、F2 或 F3 患者进行二次分析,使用 AI 数字病理 qFibrosis 评估 resmetirom 与安慰剂对组织学纤维化特征的影响。结果显示 resmetirom 80 mg 和 100 mg 的 qFS 改善率分别比安慰剂高 24.4% 和 22.3%,安慰剂校正的 qFC 平均降低分别为 -0.95 和 -1.08。结论认为 resmetirom 可显著改善 qFC、qFS 及与纤维化进展相关的个体胶原特征。
要点
- Resmetirom 80 mg 和 100 mg 的 qFS 改善率分别比安慰剂高 24.4% 和 22.3%。
- 安慰剂校正的 qFC 平均降低:80 mg 为 -0.95,100 mg 为 -1.08。
- 门管区和 Zone 2 区域的部分 qFibrosis 特征与病理纤维化分期及肝硬度相关性最强。
核心结论
- Resmetirom 治疗可显著改善 qFC、qFS 及与纤维化进展相关的个体胶原特征,支持其抗纤维化疗效。
研究设计与样本
- qFibrosis 是对 MAESTRO-NASH 多中心、双盲、安慰剂对照 III 期试验中 966 例活检确诊 MASH 且纤维化分期为 F1B、F2 或 F3 患者肝活检的二次分析。
- 基线和第 52 周活检采用二次谐波生成和双光子激发荧光显微镜评估。
主要发现
- Resmetirom 80 mg 和 100 mg 的 qFS 改善(≥1 期降低)分别比安慰剂多 24.4% 和 22.3%,并减少 qFS 恶化(≥1 期增加),两剂量名义 p ≤0.001。
- 安慰剂校正的 qFC 平均降低:80 mg 为 -0.95(95% CI -1.22 至 -0.69),100 mg 为 -1.08(95% CI -1.34 至 -0.81)。
- 30 个临床结局相关 qFibrosis 特征中有 6 个主要来自门管区和 Zone 2 区域,与病理学家评估的纤维化分期及包括肝硬度在内的生物标志物呈最强正相关。
- 门管区个体纤维化特征和鸡 wire 纤维化在 resmetirom 治疗下降低最明显。
临床怎么用
- 基于 AI 的数字病理 qFibrosis 可敏感检测 resmetirom 在 MASH 中的抗纤维化效应,超越传统序数分期。
- 门管区和 Zone 2 区域胶原重塑的定量分析可能有助于细化对 MASH 治疗相关抗纤维化效果的理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Resmetirom, a thyroid hormone beta (THR-β) agonist, has been shown to improve metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis in patients with non-cirrhotic MASH in a phase III serial liver biopsy study. In the phase III MAESTRO-NASH trial, the impact of resmetirom compared with placebo on histologic fibrosis features was evaluated using artificial intelligence (AI)-based digital pathology (qFibrosis). METHODS: qFibrosis was a secondary analysis of liver biopsies from 966 patients with biopsy-confirmed MASH and fibrosis stages F1B, F2, or F3 enrolled in the multicenter, double-blind, placebo-controlled, phase III MAESTRO-NASH trial. Biopsies from baseline and week 52 were assessed using second harmonic generation (SHG) and two-photon excitation fluorescence microscopy. Pre-specified assessments by treatment group included qFibrosis continuous values (qFC), categorical stages (qFS), and qSteatosis. Post hoc analyses evaluated regional qFibrosis features and 30 clinical outcome-associated qFibrosis features, including correlations of these features with pathologist-assessed fibrosis improvement and non-invasive tests. RESULTS: Resmetirom 80 mg and 100 mg resulted in qFS improvement (≥1-stage decrease) in 24.4% and 22.3% more patients than placebo, respectively, and reduced qFS worsening (≥1-stage increase) relative to placebo (nominal p ≤0.001 for both doses). Mean placebo-corrected reductions in qFC were -0.95 (95% CI -1.22 to -0.69) and -1.08 (95% CI -1.34 to -0.81) for the 80 mg and 100 mg doses, respectively. Six of the 30 clinical outcome-associated qFibrosis features, primarily from the portal tract and Zone 2 regions, showed the strongest positive correlations with pathologist-assessed fibrosis stage and biomarkers, including liver stiffness measures. Individual fibrosis features in the portal region and chicken wire fibrosis showed the greatest reductions with resmetirom treatment. CONCLUSIONS: Resmetirom treatment led to significant improvements in qFC, qFS, and individual collagen features associated with fibrosis progression. These digital pathology findings support the antifibrotic efficacy of resmetirom and demonstrate the potential of AI-based quantification to help define the fibrogenic response in MASH. IMPACT AND IMPLICATIONS: This study provides the first evidence from a pivotal phase III trial that AI-based digital pathology, including qFibrosis and region-specific collagen features, can sensitively detect the antifibrotic effects of resmetirom in MASH beyond conventional ordinal staging. These continuous metrics offer deeper insight into the pathophysiological mechanisms underlying fibrosis progression and reversal in MASLD, including early matrix remodeling, while enabling more granular, reproducible, and biologically plausible analyses. The ability to quantify spatially distinct patterns of collagen remodeling - particularly in the portal tract and Zone 2 regions - may refine understanding of treatment-related antifibrotic effects in MASH and help clarify how such changes may reduce progression to cirrhosis and improve clinical outcomes. CLINICAL TRIAL NUMBER: NCT03900429.
引用
- Schattenberg JM, Bedossa P, Guy CD, et al. Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial. J Hepatol. 2026. PMID: 41895606. doi:10.1016/j.jhep.2026.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。